Immunotherapy with PD-1/PD-L1 inhibitors is a new and highly appreciated anticancer immunotherapy that reactivates the body's immune system to defend against cancer cells by blocking the PD-1/PD-L1 signaling pathway [8, 9]. Here, CD274 is linked to cancer.